Prognostic impact of CRAFITY score in hepatocellular carcinoma patients treated with immune checkpoint inhibitors.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of hepatocellular carcinoma (HCC), yet identifying patients most likely to benefit remains challenging. We evaluated the prognostic significance of the C-reactive protein and alpha-fetoprotein in immunotherapy (CRAFITY) score, a composite index integrating C-reactive protein and alpha-fetoprotein, in HCC treated with ICIs. A systematic review and meta-analysis of 17 studies comprising 3,730 patients demonstrated that higher baseline CRAFITY scores were consistently associated with shorter overall and progression-free survival, as well as lower response and disease control rates. Complementing these findings, a retrospective analysis of 129 ICI-treated patients at our institution confirmed that elevated CRAFITY sco

SUBMITTER: Zhang L 

PROVIDER: S-EPMC12677073 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature